Foghorn Therapeutics, Inc. FHTX 深 沪
已收盘 10-30 16:00:00 美东时间
2.08
-0.010
-0.48%
华盛通- 最 高2.09
- 今 开2.08
- 成交量 55.56万股
- 最 低 2.005
- 昨 收 2.09
- 总市值 1.24亿
- 52周最高 7.61
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 1.79
- 委 比 -94.88%
- 总股本 5938.53万
- 历史最高 28.265
- 量 比 1.01
- 振 幅 4.07%
- 历史最低 1.79
- 每 手 1
- 风险率 1.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅405.62%！Inventiva(IVA)获Truist Securities上调目标价至18美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持Inventiva"买入"评级，目标价从13美元升至18美元；富瑞：维持Sagimet Biosciences"买入"评级，目标价从25美元升至26美元
10-05 16:26
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Argus Research raised the price target for Accenture Plc (NYSE:ACN) from $220 to $260. Argus Research analyst ...
10-02 20:58
HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $13 to $5.
10-02 19:25
BTIG Downgrades Foghorn Therapeutics to Neutral
BTIG analyst Jeet Mukherjee downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Neutral.
10-02 17:22
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data. End of Eli Lilly Collaboration and FHD-909 Development Following a review of Phase 1 data for FHD-909 (LY40...
10-02 00:17
Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $16.072 m...
08-06 19:41
Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the same period last year.
05-07 21:11
Foghorn Therapeutics Presents New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And For Selective CBP, EP300 And ARID1B Degrader Programs
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models- Selective CBP
04-22 04:15
Foghorn Therapeutics To Share New Cancer Drug Data At Major Research Conference
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will
04-09 19:10
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
